On 3 December 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, received approval from the National Medical Products Administration to commence the Phase I clinical trial of FXS0887 in China. This orally administered small molecule drug specifically targets ATR kinase activity and is intended for the treatment of advanced malignant solid tumors. According to the announcement, approximately RMB44 million had been invested in this research project as of October 2025.

Preclinical studies of FXS0887 indicated notable anti-tumor efficacy, low off-target risk, and favorable safety profiles. Currently, there is no monotherapy or combination therapy regimen with the same target approved for marketing worldwide. The announcement also highlights that drug research and development is a long-term effort with uncertainties and risks, including the potential for trial discontinuation based on safety or efficacy issues.